Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

186 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

newsclinical trialEltrombopag

新诊断的儿童免疫性血小板减少症中使用艾曲波帕：早期治疗策略的突破

By MedXY|Oct 24, 2025

这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

Hematology-Oncologyclinical trialEltrombopag

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

|

Oct 24, 2025

This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

NeurologyAlzheimer's diseaseAPOEε4

Oral Valiltramiprosate in APOEε4/ε4 Carriers with Early Alzheimer’s Disease: Insights from the Phase III APOLLOE4 Trial

By MedXY|Oct 21, 2025

This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer’s, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroup

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

Diabetes & Endocrinologyclinical trialobesity

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY|Oct 18, 2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

Diabetes & Endocrinologyclinical trialmetabolic syndrome

Monlunabant Shows Promise for Weight Loss in Obesity and Metabolic Syndrome: A Phase 2A Trial Review

By MedXY|Oct 18, 2025

This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

Nephrologyclinical trialimmunotherapy

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY|Oct 16, 2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

Diabetes & Endocrinologyclinical trialThyroid Eye Disease

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY|Oct 15, 2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial

Anesthesiologyacute kidney injuryclinical trial

Individualized Perioperative Blood Pressure Management in Major Abdominal Surgery: Insights from the IMPROVE-multi Trial

By MedXY|Oct 13, 2025

The IMPROVE-multi randomized clinical trial found that tailoring perioperative blood pressure targets to individual preoperative nighttime MAP levels did not reduce postoperative organ injury or mortality compared to routine management in h

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

Neurologyclinical trialmultiple sclerosis

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY|Jan 15, 2026

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

Gastroenterologyadherenceclinical trial

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

By MedXY|Oct 9, 2025

The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

Clinical UpdatesBiliary tract cancerchemotherapy

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY|Oct 6, 2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

Diabetes & Endocrinologyclinical trialGLP-1 receptor agonist

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY|Oct 9, 2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

Clinical Updatesclinical trialneuromodulation

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY|Oct 9, 2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson’s disease patients previously stable on continuous DBS.

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

newsclinical trialCOPD

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY|Oct 9, 2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management

Respiratorychronic rhinosinusitisclinical trial

MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management

By MedXY|Oct 9, 2025

The MACRO trial demonstrates that endoscopic sinus surgery significantly improves quality of life in adults with chronic rhinosinusitis, while long-term low-dose clarithromycin shows no added benefit over placebo.

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

Clinical Updatesclinical trial

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

By MedXY|Oct 9, 2025

The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

NeurologyCandesartanclinical trial

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

By MedXY|Oct 8, 2025

A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

newsclinical trialglioblastoma

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

By MedXY|Oct 8, 2025

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

Clinical Updatesclinical trialFFAR1

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

By MedXY|Oct 8, 2025

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Clinical Updatescisplatinclinical trial

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

By MedXY|Oct 8, 2025

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Prev 1 3 4 5 6 7 10 Next

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

MedXY News - clinical trial